

Special Issue

Multi-epitope Vaccines against Neglected, Emerging, and Re-emerging Global Diseases

Message from the Guest Editor

Neglected Global Diseases are infectious diseases and other conditions that cause physical and cognitive impairments, including maternal, infant and child health conditions; neglected tropical diseases; as well as malaria, tuberculosis, and HIV/AIDS. As climate change pushes the natural selection of pathogens and their vectors and natural reservoirs, the risk of these neglected diseases emerging within a larger global population poses an even greater threat. Vaccination is still viewed as the most effective method of preventing these infectious diseases by inducing protective immunity. This Special Issue invites articles and reviews involving multi-epitope vaccine design against neglected, emerging, and re-emerging global diseases, as well as methodologies, novel evaluation, and prediction tools for vaccine design improvement. This issue also welcomes works involving the recombinant production and in vitro and/or in vivo validation of these chimeric vaccines.

Guest Editor

Dr. Cerrone Cabanos

1. Graduate School of Agriculture, Kyoto University, Kyoto, Japan
2. Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, Japan

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/152519

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).